BackPathfinder Cell Therapy Overview

Pathfinder Cell Therapy Intangible Assets

Pathfinder Cell Therapy's intangible assets is $30K.

Get informed when a big investor buys or sells

+ Follow
Intangible Assets
$30000.00
9.09% YoYΔ $-3000.00 vs prior year quarter

Peer average

Loading

Pathfinder Cell Therapy Intangible Assets History

Loading

Pathfinder Cell Therapy vs. peers: Intangible Assets Comparison

Loading

Pathfinder Cell Therapy Intangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Pathfinder Cell Therapy (PFND) FAQ

Pathfinder Cell Therapy's intangible assets stands at $30K as of September 2015. That compares with $33K in the prior-year period — down 9.1% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Pathfinder Cell Therapy reported $30K in intangible assets versus $33K a year earlier — a 9.1% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $33K in the prior-year period — down 9.1% year over year. Sustained growth in intangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Pathfinder Cell Therapy's intangible assets evolved across reporting periods, while the comparison chart places PFND next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, intangible assets is commonly used to spot outliers. Pathfinder Cell Therapy's reading of $30K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.